Semiquantitative culture analysis during therapy for mycobacterium avium complex lung disease

American Journal of Respiratory and Critical Care Medicine

Volumn 192, Issue 6, 2015, Pages 754-760

  Griffith, David E ^a   Adjemian, Jennifer ^b,c   Brown Elliott, Barbara A ^a   Philley, Julie V ^a   Prevots, D Rebecca ^b   Gaston, Christopher ^a   Olivier, Kenneth N ^d   Wallace, Richard J ^a  

^a UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c U S PUBLIC HEALTH SERVICE   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Mycobacterial cultures; Mycobacterial therapy; Mycobacterium avium complex

Indexed keywords

MACROLIDE; QUINOLONE DERIVATIVE; ANTIINFECTIVE AGENT;

AGED; ANTIBIOTIC THERAPY; ARTICLE; ATYPICAL MYCOBACTERIOSIS; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DETERIORATION; DISEASE EXACERBATION; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEMOPTYSIS; HUMAN; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM AVIUM COMPLEX; PRIORITY JOURNAL; SPUTUM CULTURE; ADULT; BACTERIAL LOAD; BRONCHIECTASIS; DRUG MONITORING; EVALUATION STUDY; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; ODDS RATIO; PROCEDURES; RETROSPECTIVE STUDY; SPUTUM; STATISTICAL MODEL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; BRONCHIECTASIS; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; ODDS RATIO; RETROSPECTIVE STUDIES; SPUTUM; TREATMENT OUTCOME;

EID: 84942279832     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201503-0444OC     Document Type: Article

References (22)

1. Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C, Gordin F, Holland SM, Horsburgh R, Huitt G, Iademarco MF, et al.; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Diseases Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175: 367-416.
2. Published erratum appears in Am J Respir Crit Care Med 175:744-745.
3. Wallace RJ Jr, Glassroth J, Griffith DE, Olivier KN, Cook JL, Gordin F; American Thoracic Society; Medical Section of the American Lung Association. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Respir Crit Care Med 1997;156(2 Suppl):S1-S25.
4. Hales CM, Heilig CM, Chaisson R, Leung CC, Chang KC, Goldberg SV, Gordin F, Johnson JL, Muzanyi G, Saukkonen J, et al. The association between symptoms and microbiologically defined response to tuberculosis treatment. Ann Am Thorac Soc 2013;10: 18-25.
5. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT, Onyi GO, Steingrube VA, Mazurek GH. Initial clarithromycin monotherapy for Mycobacterium avium-intracellulare complex lung disease. Am J Respir Crit Care Med 1994;149:1335-1341.
6. Wallace RJ Jr, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex: the first 50 patients. Am J Respir Crit Care Med 1996;153:1766-1772.
7. Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA, Wallace RJ Jr. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin Infect Dis 2001;32:1547-1553.
8. Griffith DE, Brown BA, Murphy DT, GirardWM, Couch L,Wallace RJ Jr. Initial (6-month) results of three-times-weekly azithromycin in treatment regimens for Mycobacterium avium complex lung disease in human immunodeficiency virus-negative patients. J Infect Dis 1998;178:121-126.
9. Wallace RJ Jr, Brown-Elliott BA, McNulty S, Philley JV, Killingley J, Wilson RW, York DS, Shepherd S, Griffith DE. Macrolide/azalide therapy for nodular/bronchiectatic Mycobacterium avium complex lung disease. Chest 2014;146:276-282.
10. Wilber ST, Fu R. Risk ratios and odds ratios for common events in crosssectional and cohort studies. Acad Emerg Med 2010;17:649-651.
11. Marras TK, Prevots DR, Jamieson FB, Winthrop KL; Pulmonary MAC Outcomes Group. Variable agreement among experts regarding Mycobacterium avium complex lung disease. Respirology 2015;20: 348-351.
12. Cohn DL, Catlin BJ, Peterson KL, Judson FN, Sbarbaro JA. A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis: a twice-weekly, directly observed, and cost-effective regimen. Ann Intern Med 1990;112:407-415.
13. Lee AL, Burge A, Holland AE. Airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev 2013;5:CD008351.
14. Nicolson CH, Stirling RG, Borg BM, Button BM, Wilson JW, Holland AE. The long term effect of inhaled hypertonic saline 6% in non-cystic fibrosis bronchiectasis. Respir Med 2012;106: 661-667.
15. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir Med 2011;105: 1831-1835.
16. Vallilo CC, Terra RM, de Albuquerque AL, Suesada MM, Mariani AW, Salge JM, da Costa PB, Pêgo-Fernandes PM. Lung resection improves the quality of life of patients with symptomatic bronchiectasis. Ann Thorac Surg 2014;98:1034-1041.
17. Olveira C, Olveira G, Gaspar I, Dorado A, Cruz I, Soriguer F, Quittner AL, Espildora F. Depression and anxiety symptoms in bronchiectasis: associations with health-related quality of life. Qual Life Res 2013;22: 597-605.
18. Girón Moreno RM, Fernandes Vasconcelos G, Cisneros C, Gómez-Punter RM, Segrelles Calvo G, Ancochea J. Presence of anxiety and depression in patients with bronchiectasis unrelated to cystic fibrosis. Arch Bronconeumol 2013;49:415-420.
19. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10:1754-1760.
20. Goyal V, Chang AB. Combination inhaled corticosteroids and longacting b2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev 2014;6:CD010327.
21. Clinical Laboratory Standards Institute. Laboratory detection and identification of mycobacteria; approved guideline. CLSI document M48-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2008.
22. Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee Guidelines 1999. Thorax 2000;55:210-218.